Dr. Desheng Weng 翁德胜
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of rare tumors, including bone and soft tissue sarcomas, neuroendocrine tumors, and melanoma. Cellular immunotherapy for solid tumors.
Dr. Weng is a Chief Physician and doctoral supervisor at Sun Yat-sen University Cancer Center, serving as Deputy Director of the Department of Melanoma and Sarcoma Medical Oncology within the Biotherapy Center. A recipient of the university’s "Hundred Talents Program," Dr. Weng completed postdoctoral research at Boston University School of Medicine (2008–2012), focusing on immunotherapy for solid tumors. Dr. Weng has led or participated in multiple national and provincial grants and published over 30 SCI papers as first or corresponding author.
Name order: in Chinese the family name comes first (Weng Desheng). Papers usually list the name as Desheng Weng or Weng D.
Selected publications
90 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Cancer, 2026 (senior author): Personalized Prediction of prognosis in ebv-associated lymphoepithelioma-like carcinoma: insights from a Chinese cohort study. PubMed 41963847
- Int J Biol Sci, 2025 (senior author): Enhancing CAR-T Cell Metabolic Fitness and Memory Phenotype for Improved Efficacy against Hepatocellular Carcinoma. PubMed 40612678
- Cell Death Dis, 2025 (senior author): Tumor vascular endothelial cells promote immune escape by upregulating PD-L1 expression via crosstalk between NF-κB and STAT3 signaling pathways in nasopharyngeal carcinoma. PubMed 40000620
- BMC Cancer, 2024 (senior author): Efficacy and safety of surufatinib in the treatment of patients with neuroendocrine tumor: a real-world study in Chinese population. PubMed 39482595
- Oncol Lett, 2021 (senior author): Screening and identification of hub genes in bladder cancer by bioinformatics analysis and KIF11 is a potential prognostic biomarker. PubMed 33574944
- Cancer Manag Res, 2019 (senior author): IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma. PubMed 31410060
- J Cancer, 2018 (senior author): Clinical Effect of Adjuvant Cytokine-Induced Killer Cells Immunotherapy in Patients with Stage II-IVB Nasopharyngeal Carcinoma after Chemoradiotherapy: A propensity score analysis. PubMed 30519321
- Oncotarget, 2015 (senior author): Protein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma. PubMed 26430962
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion